Atlanta, January 26, 2025 – A potentially deadly fungus, Candida auris, is holding steady as a public health concern across the United States, with 7,046 cases reported in the last year. The Centers for Disease Control and Prevention is closely monitoring its spread, as this resilient pathogen can be difficult to diagnose and treat.
A Persistent Threat: Candida Auris Cases Remain Stable
Table of Contents
Despite a slight dip from 2024, the incidence of this dangerous fungus isn’t declining quickly enough to offer reassurance.
- In 2024, the U.S. recorded 7,046 cases of Candida auris, a slight decrease from the 7,512 cases reported in 2024.
- Nevada and California reported the highest number of cases, with 1,600 and 1,524 infections respectively.
- Candida auris is often resistant to common antifungal medications, requiring specialized treatment with equinocandins.
- The fungus spreads through direct contact and contaminated surfaces, making hospitals a key area of concern.
Nevada and California continue to be hotspots for the fungus, with 1,600 and 1,524 cases reported, respectively. texas reported 811 cases. Notably, Florida and Alabama reported no cases. However,the fungus isn’t limited to the western states; cases have also been identified on the East Coast,with 377 reported in Georgia and 21 in North Carolina.
Symptoms and Diagnosis
According to Medline Plus, an official U.S. government source,the difficulty in identifying Candida auris stems from its symptom overlap with other infections. Common symptoms include fever, chills, and fatigue, but these are non-specific and can indicate a wide range of illnesses.In severely ill patients, differentiating symptoms caused by the fungus can be even more challenging, as they are frequently enough battling multiple health issues simultaneously.
Treatment and Prevention
Candida auris is frequently enough resistant to commonly used antifungal medications. When a diagnosis is confirmed, treatment typically involves a specific class of antifungal drugs called equinocandins. In cases where the fungus demonstrates resistance, higher doses or combinations with other drugs may be necesary.
The fungus spreads primarily through direct contact with infected individuals or contaminated objects and medical equipment, such as railings and bedside tables in healthcare facilities. Consequently, infections are more frequent among hospitalized patients, particularly those using devices like breathing tubes, feeding tubes, or intravenous catheters.
Individuals with weakened immune systems or chronic medical conditions are at increased risk of contracting candida auris. A history of frequent antibiotic use also elevates the risk. Medline Plus emphasizes that infection is “rare in healthy people,” but warns that C. auris infections that spread to the bloodstream and organs in very sick people can frequently enough lead to death.
